Maze Therapeutics (MAZE) Share-based Compensation (2024 - 2026)

Maze Therapeutics has reported Share-based Compensation for 3 years, with the latest figure at $58.0 million in Q1 2026.

• Quarterly Share-based Compensation rose 1697.89% year-over-year to $58.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.0 million (up 449.14% YoY) and the FY2025 annual result came in at $28.4 million, down 5.33% from the prior year.
• Share-based Compensation climbed to $58.0 million in Q1 2026 per MAZE's latest filing, from $6.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $58.0 million in Q1 2026 and troughed at $2.1 million in Q2 2024.
• A 3-year average of $12.3 million and a median of $3.2 million in 2025 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation jumped 39.65% in 2025, then soared 1697.89% in 2026.
• Over 3 years, Share-based Compensation stood at $2.9 million in 2024, then jumped by 113.01% to $6.1 million in 2025, then soared by 855.05% to $58.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $58.0 million, $6.1 million, and $30.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.